🎯 Targeted. 💉 Immune. 🔬 Precise. The new face of early NSCLC — ESMO 2025 ⚡ 🔑 Key updates 🧬 Biomarker testing (EGFR, ALK, PD-L1) now mandatory in stage IB–III 💊 Adjuvant targeted therapy ADAURA → Osimertinib (EGFR) ALINA → Alectinib (ALK) 💉 Peri-op immunotherapy

CR on T-DXd = a survival curve of its own. 🩸 HER2+ MBC • DESTINY-Breast Pooled Analysis 🔍 Study Snapshot Pooled DESTINY-Breast01 + 02 + 03 (n=834) evaluating best confirmed response vs outcomes & biomarkers with T-DXd 5.4 mg/kg. Response distribution: •🟢 CR: 15 percent

KOMET-001 study (Ziftomenib)nicely summarised by Oncology Brothers

🧬 DNA vs RNA NGS - Music sheet vs Orchestra! 🎼 🔹 DNA NGS = The Music sheet 🏗️📜 Think of DNA as the music sheet — the written plan. 🧩 Detects SNVs, indels, CNVs, MSI, TMB 🔍 Finds hidden drivers (EGFR, BRCA, KRAS) 🧱 Stable → relatively unchanging ⚠️ But → Can’t confirm

Makeup ate today? Nah . T-DXd ate today 💅💥 (HER2-low, HER2-ultralow, HER2, pan tumor - it eats regardless) Maybe the most groundbreaking oncology drug since Imatinib ? Sara Tolaney OncoAlert Oncology Brothers ASCO Dana-Farber’s Breast Oncology Center #MedTwitter #oncotwitter #breastcancer

🚨 MENIN SHOWDOWN IN AML — Revumenib vs Ziftomenib 🚨 Two menin inhibitors, two different vibes 👇 🧬 1. Who gets what? •Revumenib → KMT2A-r and NPM1-mut AML •Ziftomenib → NPM1-mut AML only 🔥 2. Response CR/CRh: •Revumenib: 21–23% •Ziftomenib: 25% DoR: •Revumenib: